keyword
MENU ▼
Read by QxMD icon Read
search

BCG immunotherapy

keyword
https://www.readbyqxmd.com/read/27893591/endophthalmitis-in-a-patient-treated-with-bacillus-calmette-gu%C3%A3-rin-immunotherapy
#1
Julie Vadboncoeur, Sébastien Olivier, Hafid Soualhine, Annie-Claude Labbé, Marie-Lyne Bélair
BACKGROUND: Intravesical Bacillus Calmette-Guérin (BCG) instillation has become one of the mainstays of adjunctive therapy in the treatment of superficial bladder cancer. Ophthalmologic complications are rare, but few cases are reported in the literature. METHODS: Retrospective observational case report. RESULTS: The authors report a case of unilateral Mycobacterium bovis BCG endophthalmitis after intravesical BCG instillations. Despite appropriate systemic antituberculous and corticosteroid therapy, the patient almost completely lost sight in the affected eye...
November 23, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#2
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27833923/low-dose-bcg-infection-as-a-model-for-macrophage-activation-maintaining-cell-viability
#3
Leslie Chávez-Galán, Dominique Vesin, Denis Martinvalet, Irene Garcia
Mycobacterium bovis BCG, the current vaccine against tuberculosis, is ingested by macrophages promoting the development of effector functions including cell death and microbicidal mechanisms. Despite accumulating reports on M. tuberculosis, mechanisms of BCG/macrophage interaction remain relatively undefined. In vivo, few bacilli are sufficient to establish a mycobacterial infection; however, in vitro studies systematically use high mycobacterium doses. In this study, we analyze macrophage/BCG interactions and microenvironment upon infection with low BCG doses and propose an in vitro model to study cell activation without affecting viability...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27803478/development-of-a-drug-delivery-system-for-cancer-immunotherapy
#4
Takashi Nakamura
 Delivery systems are a powerful technology for enhancing the effect of cancer immunotherapy. We have been in the process of developing lipid-based delivery systems for controlling the physical properties and dynamics of immunofunctional molecules such as antigens and adjuvants. The lipid nanoparticulation of these molecules improves their physical properties, resulting in a good water dispensability, greater stability, and small size. The cell wall skeleton of bacille Calmette-Guerin (BCG-CWS) could be used to replace live BCG as a drug for treating bladder cancer, but problems associated with the physical properties of BCG-CWS have prevented its use...
2016: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/27785423/immunotherapy-in-urothelial-carcinoma-fade-or-future-standard
#5
REVIEW
Johannes Breyer, Maximilian Burger, Wolfgang Otto
Immunotherapy of non-muscle-invasive bladder carcinoma by Bacillus-Calmette-Guérin (BCG) instillation is a well-established treatment option since decades. Despite this fact, the immunocellular basis was first studied in recent years. New aspects of immunotherapy, also for progressed bladder carcinoma, might follow promising research on immunological targets.
October 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/27775397/dynamical-properties-and-tumor-clearance-conditions-for-a-nine-dimensional-model-of-bladder-cancer-immunotherapy
#6
K E Starkov, Svetlana Bunimovich-Mendrazitsky
Understanding the global interaction dynamics between tumor and the immune system plays a key role in the advancement of cancer therapy. Bunimovich-Mendrazitsky et al. (2015) developed a mathematical model for the study of the immune system response to combined therapy for bladder cancer with Bacillus Calmette-Guérin (BCG) and interleukin-2 (IL-2) . We utilized a mathematical approach for bladder cancer treatment model for derivation of ultimate upper and lower bounds and proving dissipativity property in the sense of Levinson...
October 1, 2016: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/27750214/genomic-characterization-of-high-risk-non-muscle-invasive-bladder-cancer
#7
Joshua J Meeks, Benedito A Carneiro, Sachin G Pai, Daniel T Oberlin, Alfred Rademaker, Kyle Fedorchak, Sohail Balasubramanian, Julia Elvin, Nike Beaubier, Francis J Giles
The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted selective next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of cancers that responded to intravesical therapy and those that progressed to muscle-invasive or advanced disease. DNA was extracted from paraffin-embedded sections from 25 HR-NMIBCs (22 with T1HG; 3 with TaHG with or without carcinoma in situ). Ten patients with HR-NMIBC developed progression (pT2+ or N+) ("progressors")...
October 14, 2016: Oncotarget
https://www.readbyqxmd.com/read/27676732/total-hip-arthroplasty-infection-due-to-mycobacterium-bovis-after-bcg-therapy
#8
Alban Fouasson-Chailloux, Benoit Metayer, Pierre Menu, Lydie Khatchatourian, Joelle Glemarec, Marc Dauty
OBJECTIVE: The loosening of total joint replacement is a frequent complication after total hip arthroplasty (THA). Septic osteolysis should always be feared. We report here a rare case of hip arthroplasty infection due to Mycobacterium bovis after Bacillus Calmette-Guerin (BCG) therapy in a context of bladder cancer. OBSERVATIONS: A 70-year-old man was referred to the department of rheumatology in September 2015, because of a total functional disability of the left lower limb...
September 2016: Annals of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27647081/mitomycin-c-new-strategies-to-improve-efficacy-of-a-well-known-therapy
#9
Mauro Ragonese, Marco Racioppi, Pier Francesco Bassi, Luca Di Gianfrancesco, Niccolò Lenci, Alessio Filianoti, Salvatore M Recupero
Mitomycin C (MMC) as an intravesical chemotherapeutic agent is a well-known option for treatment of nonmuscle invasive bladder cancer (NMIBC) recurrence; it is probably the most commonly used agent given its low rate of side effects and its efficacy.Both the American Urologic Association (AUA) and European Association of Urology (EAU) consider MMC as a standard treatment for immediate single-dose postoperative treatment and for adjuvant therapy in low and intermediate-risk NMIBC.Despite the popularity of this agent in the treatment of NMIBCs, many questions regarding the optimal approach to MMC therapy remain unanswered and the schedule widely used is empirical...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27563657/immunobiology-and-immunotherapy-in-genitourinary-malignancies
#10
REVIEW
Marinos Tsiatas, Petros Grivas
Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant prostate cancer (mCRPC), based on a phase III trial showing overall survival (OS) benefit compared to placebo...
July 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27525288/lactobacillus-rhamnosus-gg-activation-of-dendritic-cells-and-neutrophils-depends-on-the-dose-and-time-of-exposure
#11
Shirong Cai, Matheswaran Kandasamy, Juwita N Rahmat, Sin Mun Tham, Boon Huat Bay, Yuan Kun Lee, Ratha Mahendran
This study evaluates the ability of Lactobacillus rhamnosus GG (LGG) to activate DC and neutrophils and modulate T cell activation and the impact of bacterial dose on these responses. Murine bone marrow derived DC or neutrophils were stimulated with LGG at ratios of 5 : 1, 10 : 1, and 100 : 1 (LGG : cells) and DC maturation (CD40, CD80, CD86, CD83, and MHC class II) and cytokine production (IL-10, TNF-α, and IL-12p70) were examined after 2 h and 18 h coculture and compared to the ability of BCG (the present immunotherapeutic agent for bladder cancer) to stimulate these cells...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27516352/the-clinical-value-of-psa-increase-during-intravesical-adjuvant-therapy-for-nonmuscle-invasive-bladder-cancer
#12
Vincenzo Serretta, Cristina Scalici Gesolfo, Fabrizio Di Maida, Giovanni Caruana, Lorenzo Rocchini, Marco Moschini, Renzo Colombo, Alchiede Simonato
INTRODUCTION: Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered...
September 26, 2016: Urologia
https://www.readbyqxmd.com/read/27460757/immunotherapy-for-the-treatment-of-urothelial-carcinoma
#13
REVIEW
Nicholas M Donin, Andrew T Lenis, Stuart Holden, Alexandra Drakaki, Allan Pantuck, Arie Belldegrun, Karim Chamie
PURPOSE: We review the biological mechanisms of action, clinical safety and efficacy of immunotherapies for urothelial carcinoma. We also describe current areas of research in immunotherapy, and highlight ongoing trials and promising and novel investigational agents. MATERIALS AND METHODS: Data were obtained by a search of PubMed®, ClinicalTrials.gov and Cochrane databases for English language articles published through February 2016. Applicable abstracts from recent Society of Urologic Oncology, European Association of Urology, American Urological Association and ASCO® meetings were used...
July 25, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27458527/nonmuscle-invasive-bladder-cancer-a-primer-on-immunotherapy
#14
Mahir Maruf, Sam J Brancato, Piyush K Agarwal
Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer...
June 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/27428950/immunogenic-human-papillomavirus-pseudovirus-mediated-suicide-gene-therapy-for-bladder-cancer
#15
Rim Hojeij, Sonia Domingos-Pereira, Marianne Nkosi, Dalila Gharbi, Laurent Derré, John T Schiller, Patrice Jichlinski, Denise Nardelli-Haefliger
Bladder cancer is the second most common urological malignancy in the world. In 70% of cases it is initially diagnosed as non-muscle-invasive bladder cancer (NMIBC) and it is amenable to local treatments, with intravesical (IVES) Bacillus-Calmette-Guerin (BCG) immunotherapy being routinely used after transurethral resection of the lesion. However, this treatment is associated with significant side-effects and treatment failures, highlighting the necessity of novel strategies. One potent approach is the suicide-gene mediated therapy/prodrug combination, provided tumor-specificity can be ensured and anti-tumor immune responses induced...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27412241/antitumour-responses-induced-by-a-cell-based-reovirus-vaccine-in-murine-lung-and-melanoma-models
#16
Ciorsdan A Campion, Declan Soden, Patrick F Forde
BACKGROUND: The ever increasing knowledge in the areas of cell biology, the immune system and the mechanisms of cancer are allowing a new phase of immunotherapy to develop. The aim of cancer vaccination is to activate the host immune system and some success has been observed particularly in the use of the BCG vaccine for bladder cancer as an immunostimulant. Reovirus, an orphan virus, has proven itself as an oncolytic virus in vitro and in vivo. Over 80 % of tumour cell lines have been found to be susceptible to Reovirus infection and it is currently in phase III clinical trials...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27389279/increased-toll-like-receptors-and-p53-levels-regulate-apoptosis-and-angiogenesis-in-non-muscle-invasive-bladder-cancer-mechanism-of-action-of-p-mapa-biological-response-modifier
#17
Patrick Vianna Garcia, Fábio Rodrigues Ferreira Seiva, Amanda Pocol Carniato, Wilson de Mello Júnior, Nelson Duran, Alda Maria Macedo, Alexandre Gabarra de Oliveira, Rok Romih, Iseu da Silva Nunes, Odilon da Silva Nunes, Wagner José Fávaro
BACKGROUND: The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of new drugs. Although agents like mitomycin C and BCG are routinely used, there is a need for more potent and/or less-toxic agents. In this scenario, a new perspective is represented by P-MAPA (Protein Aggregate Magnesium-Ammonium Phospholinoleate-Palmitoleate Anhydride), developed by Farmabrasilis (non-profit research network)...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27376138/summary-and-recommendations-from-the-national-cancer-institute-s-clinical-trials-planning-meeting-on-novel-therapeutics-for-non-muscle-invasive-bladder-cancer
#18
Seth P Lerner, Dean F Bajorin, Colin P Dinney, Jason A Efstathiou, Susan Groshen, Noah M Hahn, Donna Hansel, David Kwiatkowski, Michael O'Donnell, Jonathan Rosenberg, Robert Svatek, Jeffrey S Abrams, Hikmat Al-Ahmadie, Andrea B Apolo, Joaquim Bellmunt, Margaret Callahan, Eugene K Cha, Charles Drake, Jonathan Jarow, Ashish Kamat, William Kim, Margaret Knowles, Bhupinder Mann, Luigi Marchionni, David McConkey, Lisa McShane, Nilsa Ramirez, Andrew Sharabi, Arlene H Sharpe, David Solit, Catherine M Tangen, Abdul Tawab Amiri, Eliezer Van Allen, Pamela J West, J A Witjes, Diane Zipursky Quale
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing on immunotherapy and molecular targeted therapy...
2016: Bladder Cancer
https://www.readbyqxmd.com/read/27345655/bladder-cancer
#19
Ashish M Kamat, Noah M Hahn, Jason A Efstathiou, Seth P Lerner, Per-Uno Malmström, Woonyoung Choi, Charles C Guo, Yair Lotan, Wassim Kassouf
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure...
June 23, 2016: Lancet
https://www.readbyqxmd.com/read/27333654/-bcg-immunotherapy-against-non-muscle-invasive-bladder-cancer-recent-results-current-studies-and-future-perspectives
#20
REVIEW
Ario Takeuchi, Masaki Shiota, Katsunori Tatsugami, Akira Yokomizo, Masatoshi Eto
No abstract text is available yet for this article.
January 2016: Fukuoka Igaku Zasshi, Hukuoka Acta Medica
keyword
keyword
7100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"